A Canadian center’s experience on whole-gland salvage therapy for radio-recurrent prostate cancer with various modalities

Authors

  • Joseph L. Chin Department of Urology, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada
  • J. Jesus Cendejas-Gomez Department of Urology, University of Western Ontario, London Health Sciences Centre, London, Ontario, Canada https://orcid.org/0000-0003-0833-3144
  • Max Peters Department of Radiotherapy, University Medical Center Utrecht https://orcid.org/0000-0002-7981-5768

DOI:

https://doi.org/10.5489/cuaj.8331

Keywords:

Prostate cancer, Radio-recurrent prostate cancer, Salvage ablative therapies, Focal salvage therapy

Abstract

Salvage radical prostatectomy for localized radio-recurrent prostate cancer had historically, in the 1980s and 1990s, been associated with relatively high morbidity. Thus, there was an impetus to explore the role of minimally invasive ablative therapies for this patient population. To review the Canadian experience of salvage ablative therapy for radio-recurrent prostate cancer, this article chronicles the quarter-century results of whole-gland salvage ablation therapies at one academic center, Western University (UWO), with emphasis on cryoablation, high-intensity focused ultrasound (HIFU), and interstitial laser photodynamic therapy (PDT). As well, recent developments in other salvage techniques and advanced functional imaging will be reviewed, and the evidence for and increasing acceptance of focal salvage therapy will be briefly discussed.

Downloads

Download data is not yet available.

Downloads

Published

2023-08-29

How to Cite

Chin, J. L., Cendejas-Gomez, J. J. ., & Peters, M. . (2023). A Canadian center’s experience on whole-gland salvage therapy for radio-recurrent prostate cancer with various modalities. Canadian Urological Association Journal, 17(12), 425–31. https://doi.org/10.5489/cuaj.8331

Issue

Vol. 17 No. 12 (2023): CUAJ December

Section

Review

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.